The most common over-the-counter sleep aids, those containing diphenhydramine or doxylamine, are linked to an increased risk of dementia with long-term use. Routine use of sleep medications is associated with a roughly 30% higher risk of developing dementia compared to never using them. The connection isn’t definitive proof of cause and effect, but the evidence is consistent enough that major health organizations flag these drugs as potentially inappropriate for older adults.
Which Sleep Aids Are Linked to Dementia Risk
The two active ingredients in most OTC sleep aids are diphenhydramine (found in Benadryl, ZzzQuil, Tylenol PM, and Advil PM) and doxylamine succinate (found in Unisom SleepTabs). Both are sedating antihistamines, and both have anticholinergic properties, meaning they block a chemical messenger called acetylcholine in the brain and nervous system.
Acetylcholine plays a central role in memory, learning, and attention. Blocking it is what makes you drowsy, but it’s also what creates cognitive side effects like confusion and forgetfulness, particularly in older adults. These short-term effects are well established. The deeper concern is whether years of intermittent or nightly use could contribute to lasting cognitive decline.
Not all OTC sleep aids carry this concern. Melatonin, valerian root, and magnesium work through entirely different mechanisms and do not block acetylcholine. The risk appears specific to anticholinergic drugs.
What the Research Shows
Multiple large, long-term studies have found a consistent association between regular sleep medication use and dementia. A nationally representative U.S. study found that routine sleep medication use was associated with a 30% increased risk of developing dementia over a 10-year follow-up period, even after adjusting for age, health conditions, and other factors. A separate study of older adults found that diphenhydramine use was associated with a 22% increased rate of delirium among hospitalized patients, while community-dwelling older adults who used these medications scored lower on cognitive function tests over a decade.
The risk appears to increase with cumulative exposure. Researchers use a measure called “total standardized daily doses” to quantify how much anticholinergic medication a person has taken over time. Epidemiological studies have found that exceeding roughly 1,095 standardized doses over 10 years, equivalent to taking a standard dose daily for about three years, crosses a threshold associated with significantly higher dementia risk. In one study of older adults, 72% had already exceeded that threshold.
These are observational studies, which means they can show a pattern but can’t prove that the sleep aids directly caused dementia. It’s possible that people who rely heavily on sleep aids have underlying sleep disorders, and poor sleep itself is a known risk factor for cognitive decline. Researchers have tried to account for this statistically, and the association with sleep medication persists, but the possibility of confounding factors hasn’t been fully ruled out.
How Anticholinergics May Affect the Brain
The most straightforward explanation is chronic cholinergic depletion. When you repeatedly block acetylcholine over months or years, the brain’s signaling network for memory and learning may be degraded in ways that accumulate over time. This is especially concerning because Alzheimer’s disease itself involves a breakdown of the acetylcholine system, and the medications used to treat Alzheimer’s actually work by boosting acetylcholine levels. In other words, common sleep aids do the biochemical opposite of Alzheimer’s drugs.
But that may not be the full picture. Research from a large nested case-control study published in JAMA Internal Medicine suggests that vascular changes and inflammation in the brain may also play a role, meaning the damage pathway might not be limited to acetylcholine disruption alone. This could help explain why the risk doesn’t seem to be confined to Alzheimer’s-type dementia specifically.
Can the Damage Be Reversed?
This is one of the most important questions, and the answer is mixed. The traditional medical view has been that anticholinergic-related cognitive impairment is reversible once you stop taking the medication. Short-term fogginess and confusion do tend to clear up after discontinuation. However, a prospective cohort study published in JAMA Internal Medicine found that the elevated dementia risk may persist even after stopping the drugs. This suggests that for people who have used these medications heavily over many years, simply quitting may not fully undo the accumulated effect.
That said, stopping sooner is almost certainly better than continuing. The evidence consistently shows that higher cumulative exposure means higher risk, so reducing your total lifetime use matters regardless of whether some residual risk remains.
Safer Alternatives for Sleep
If you’ve been reaching for diphenhydramine or doxylamine regularly, several alternatives don’t carry anticholinergic concerns.
- Melatonin helps regulate your natural sleep-wake cycle. Its effects are typically mild, and it works best for shifting your sleep timing (like jet lag) or shortening the time it takes to fall asleep. Side effects can include headaches, nausea, and daytime drowsiness, but it does not block acetylcholine.
- Valerian root is a plant-based supplement sometimes used as a sleep aid. Study results are mixed on its effectiveness, but side effects appear to be mild, mainly headache and weakness.
- Cognitive behavioral therapy for insomnia (CBT-I) is considered the first-line treatment for chronic insomnia by most sleep medicine guidelines. It addresses the thought patterns and habits that keep you awake, and its effects tend to last longer than any medication.
None of these carry the dementia-related concerns associated with anticholinergic sleep aids. For occasional sleepless nights, melatonin is a reasonable option. For ongoing insomnia, CBT-I addresses the root problem rather than masking it with sedation.
Who Should Be Most Concerned
The risk is most relevant for people over 65, who are more sensitive to anticholinergic effects and already at higher baseline risk for dementia. Both the American Geriatrics Society and the Mayo Clinic flag OTC sleep aids containing antihistamines as potentially risky for this age group. Older adults metabolize these drugs more slowly, so the active ingredient stays in the body longer and has a stronger cognitive impact.
Younger adults who take diphenhydramine occasionally for a rough night of sleep are in a very different category from a 70-year-old who has taken it nightly for a decade. The research consistently points to cumulative exposure as the key variable. Occasional use carries far less concern than habitual, long-term reliance.
If you’re currently using an anticholinergic sleep aid most nights and have been doing so for months or years, that pattern is worth changing. Tapering off rather than stopping abruptly can help avoid rebound insomnia, and transitioning to a non-anticholinergic option or behavioral approach can protect both your sleep and your long-term cognitive health.